Genzyme Will Act Fast To Design Post-Market Myozyme Study By Review Date

The on-time approval of a larger production scale of Genzyme's Pompe Disease biologic Myozyme could hinge on development of a post-market study protocol prior to the Nov. 29 PDUFA date